Cancer of unknown primary site: A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan

Hisakazu Nishimori, Shunji Takahashi, Katsuyuki Kiura, Daisuke Ennishi, Takayuki Kobayashi, Koji Sano, Eiji Shinozaki, Masahiro Yokoyama, Yuko Mishima, Yasuhito Terui, Keisho Chin, Nobuyuki Mizunuma, Yoshinori Ito, Seiichiro Nishimura, Kengo Takeuchri, Yuichi Ishikawa, Masahiko Oguchi, Mitsune Tanimoto, Kiyohiko Hatake

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalActa Medica Okayama
Volume64
Issue number5
Publication statusPublished - 2010

Fingerprint

docetaxel
Chemotherapy
Cisplatin
Toxicity
Japan
Liver
Neoplasms
Bone
Therapeutics
Drug Therapy
Survival
Hyponatremia
Survival Rate
Lymph Nodes

Keywords

  • Cancer of unknown primary site (CUP)
  • Cisplatin
  • Docetaxel
  • Prognosis

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cancer of unknown primary site : A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan. / Nishimori, Hisakazu; Takahashi, Shunji; Kiura, Katsuyuki; Ennishi, Daisuke; Kobayashi, Takayuki; Sano, Koji; Shinozaki, Eiji; Yokoyama, Masahiro; Mishima, Yuko; Terui, Yasuhito; Chin, Keisho; Mizunuma, Nobuyuki; Ito, Yoshinori; Nishimura, Seiichiro; Takeuchri, Kengo; Ishikawa, Yuichi; Oguchi, Masahiko; Tanimoto, Mitsune; Hatake, Kiyohiko.

In: Acta Medica Okayama, Vol. 64, No. 5, 2010, p. 285-291.

Research output: Contribution to journalArticle

Nishimori, H, Takahashi, S, Kiura, K, Ennishi, D, Kobayashi, T, Sano, K, Shinozaki, E, Yokoyama, M, Mishima, Y, Terui, Y, Chin, K, Mizunuma, N, Ito, Y, Nishimura, S, Takeuchri, K, Ishikawa, Y, Oguchi, M, Tanimoto, M & Hatake, K 2010, 'Cancer of unknown primary site: A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan', Acta Medica Okayama, vol. 64, no. 5, pp. 285-291.
Nishimori, Hisakazu ; Takahashi, Shunji ; Kiura, Katsuyuki ; Ennishi, Daisuke ; Kobayashi, Takayuki ; Sano, Koji ; Shinozaki, Eiji ; Yokoyama, Masahiro ; Mishima, Yuko ; Terui, Yasuhito ; Chin, Keisho ; Mizunuma, Nobuyuki ; Ito, Yoshinori ; Nishimura, Seiichiro ; Takeuchri, Kengo ; Ishikawa, Yuichi ; Oguchi, Masahiko ; Tanimoto, Mitsune ; Hatake, Kiyohiko. / Cancer of unknown primary site : A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan. In: Acta Medica Okayama. 2010 ; Vol. 64, No. 5. pp. 285-291.
@article{ef5ce0418e7c44a1b7bde38212053ee4,
title = "Cancer of unknown primary site: A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan",
abstract = "We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5{\%}, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6{\%}. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.",
keywords = "Cancer of unknown primary site (CUP), Cisplatin, Docetaxel, Prognosis",
author = "Hisakazu Nishimori and Shunji Takahashi and Katsuyuki Kiura and Daisuke Ennishi and Takayuki Kobayashi and Koji Sano and Eiji Shinozaki and Masahiro Yokoyama and Yuko Mishima and Yasuhito Terui and Keisho Chin and Nobuyuki Mizunuma and Yoshinori Ito and Seiichiro Nishimura and Kengo Takeuchri and Yuichi Ishikawa and Masahiko Oguchi and Mitsune Tanimoto and Kiyohiko Hatake",
year = "2010",
language = "English",
volume = "64",
pages = "285--291",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Cancer of unknown primary site

T2 - A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan

AU - Nishimori, Hisakazu

AU - Takahashi, Shunji

AU - Kiura, Katsuyuki

AU - Ennishi, Daisuke

AU - Kobayashi, Takayuki

AU - Sano, Koji

AU - Shinozaki, Eiji

AU - Yokoyama, Masahiro

AU - Mishima, Yuko

AU - Terui, Yasuhito

AU - Chin, Keisho

AU - Mizunuma, Nobuyuki

AU - Ito, Yoshinori

AU - Nishimura, Seiichiro

AU - Takeuchri, Kengo

AU - Ishikawa, Yuichi

AU - Oguchi, Masahiko

AU - Tanimoto, Mitsune

AU - Hatake, Kiyohiko

PY - 2010

Y1 - 2010

N2 - We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.

AB - We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.

KW - Cancer of unknown primary site (CUP)

KW - Cisplatin

KW - Docetaxel

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=78149433869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149433869&partnerID=8YFLogxK

M3 - Article

C2 - 20975761

AN - SCOPUS:78149433869

VL - 64

SP - 285

EP - 291

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -